Aarti Pharmalabs' Q3 FY 2025-26 Quarterly Results
- 10 Feb 2026
Result Summary
- Aarti Pharmalabs Ltd reported a 3.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 20.4%.
- Its expenses for the quarter were down by 2.1% QoQ and 16.1% YoY.
- The net profit increased 71.8% QoQ and decreased 35.2% YoY.
- The earnings per share (EPS) of Aarti Pharmalabs Ltd stood at 5.29 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 431.90 | 418.39 | 542.81 | 3.2% | -20.4% |
Total Expenses | 371.16 | 379.06 | 442.18 | -2.1% | -16.1% |
Profit Before Tax | 57.94 | 39.33 | 100.63 | 47.3% | -42.4% |
Tax | 14.91 | 10.77 | 26.64 | 38.4% | -44.0% |
Profit After Tax | 47.96 | 27.92 | 73.99 | 71.8% | -35.2% |
Earnings Per Share | 5.29 | 3.08 | 8.16 | 71.8% | -35.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Aarti Pharmalabs Ltd is a company that operates within the pharmaceutical industry. The company is primarily engaged in the development, manufacturing, and supply of a wide range of pharmaceutical products. These products can include active pharmaceutical ingredients (APIs), intermediates, and formulations. The pharmaceutical industry is characterized by rigorous regulatory standards and a focus on innovation and quality. While specific recent major developments for Aarti Pharmalabs Ltd are not available, companies in this sector typically experience changes in regulatory approvals, market expansions, or strategic partnerships, which can impact their financial performance and market position.
Revenue
During the third quarter of the financial year 2026 (Q3FY26), Aarti Pharmalabs Ltd reported total income of ₹431.90 crores. This represents a quarter-over-quarter (QoQ) increase of 3.2% compared to the second quarter of the financial year 2026 (Q2FY26), when total income was ₹418.39 crores. However, on a year-over-year (YoY) basis, total income decreased by 20.4% from ₹542.81 crores in the third quarter of the financial year 2025 (Q3FY25). The fluctuations in revenue could be attributed to various factors such as changes in market demand, pricing strategies, or competitive dynamics within the pharmaceutical industry.
Profitability
Aarti Pharmalabs Ltd's profit before tax (PBT) for Q3FY26 was ₹57.94 crores, marking a significant QoQ increase of 47.3% from ₹39.33 crores in Q2FY26. In comparison to Q3FY25, the PBT decreased by 42.4% from ₹100.63 crores. The tax expense for Q3FY26 was ₹14.91 crores, which also showed a QoQ increase of 38.4% from ₹10.77 crores in Q2FY26, but a YoY decrease of 44.0% from ₹26.64 crores in Q3FY25. Consequently, the profit after tax (PAT) for Q3FY26 stood at ₹47.96 crores, reflecting a 71.8% QoQ growth from ₹27.92 crores in Q2FY26, while experiencing a 35.2% YoY decline from ₹73.99 crores in Q3FY25. The earnings per share (EPS) in Q3FY26 was ₹5.29, aligning with the same percentage changes as the PAT, indicating the company's earnings performance relative to its share count.
Operating Metrics
Total expenses for Aarti Pharmalabs Ltd in Q3FY26 amounted to ₹371.16 crores, showing a 2.1% decrease from ₹379.06 crores in Q2FY26. When compared to Q3FY25, total expenses decreased by 16.1% from ₹442.18 crores. The reduction in expenses both QoQ and YoY could reflect the company's cost management efforts or operational efficiencies. The operating metrics highlight the company's ability to manage its expenses in relation to its revenue, impacting its overall profitability. While specific financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio are not provided in the data, these metrics are crucial for assessing the company's financial health and operational efficiency.